4-Piperidinopiperidine-resistant lymphoma cells were resistant to dexamethasone- and A23187-induced apoptosis

Cancer Letters

Volumn 127, Issue 1-2, 1998, Pages 147-153

  Onishi, Yoshiaki ^a   Oguro, Masao ^b   Kizaki, Harutoshi ^a  

^a TOKYO DENTAL COLLEGE   (Japan)

^b Niigata Hosp   (Japan)

Author keywords

4 Piperidinopiperidine; Apoptosis; CPT 11; Drug resistance; Topoisomerase

Indexed keywords

4 PIPERIDINOPIPERIDINE; CALCIMYCIN; DEXAMETHASONE; IRINOTECAN; PIPERIDINE DERIVATIVE; PROTEIN BAX; PROTEIN BCL 2; PROTEIN P53; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; CONTROLLED STUDY; CROSS RESISTANCE; DRUG RESISTANCE; GENE EXPRESSION; LYMPHOMA CELL; LYMPHOMA CELL LINE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

APOPTOSIS; CALCIMYCIN; CAMPTOTHECIN; DEXAMETHASONE; DNA FRAGMENTATION; DRUG RESISTANCE; HUMANS; LYMPHOMA; PIPERIDINES; TUMOR CELLS, CULTURED;

EID: 0032523885     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0304-3835(98)00029-9     Document Type: Article

References (20)

1. Wall M.E., Wani M.C., Cook C.E., Palmer K.H., Mcphail A.T., Sim G.A. Plant antitumor agents I. The isolation and structure of camptothecin, a novel alkaloidal leukemia and tumor inhibitor from Camptotheca acuminata. J. Am. Chem. Sci. 88:1966;3888-3890.
2. Gallo R.C., Whang-Peng J., Richard H. Studies on the antitumor activity, mechanism of action, and cell cycle effects of camptothecin. J. Natl. Cancer Inst. 73:1973;385-405.
3. Kunimoto T., Nitta K., Tanaka T., Uehara N., Baba H., Takeuchi M., Yokokura T., Sawada S., Miyasaka T., Mutai M. Antitumor activity of 7-ethyl-10-[4-(1-piperidino)-1-piperidino]-carbonylcamptothecin, a water-soluble derivative of camptothecin, against murine tumors. Cancer Res. 47:1987;5944-5947.
4. Kawato Y., Aonuma M., Hirota Y., Kuga H., Sato K. Intracellular roles of SN-38, a metabolite of the camptothecin derivative CPT-11, in the antitumor effect of CPT-11. Cancer Res. 51:1991;4187-4191.
5. Slichenmyer W.J., Rowinsky E.K., Donehower R.C., Kaufmann S.H. The current status of camptothecin analogues as antitumor agents. J. Natl. Cancer Inst. 85:1993;271-291.
6. Sugimoto Y., Tsukahara S., Oh-hara T., Isoe T., Tsuruo T. Decreased expression of DNA topoisomerase I in camptothecin-resistant tumor cell lines as determined by a monoclonal antibody. Cancer Res. 50:1990;6925-6930.
7. Tamura H., Kohchi C., Yamada R., Ikeda T., Koiwai O., Patterson E., Keene J.D., Okada K., Kjeldsen E., Nishikawa K., Andoh T. Molecular cloning of a cDNA of a camptothecin-resistant human DNA topoisomerase I and identification of mutation sites. Nucleic Acids Res. 19:1991;69-75.
8. Tanizawa A., Bertrand R., Kohlhagen G., Tabuchi A., Jenkins J., Pommier Y. Cloning of Chinese hamster DNA topoisomerase I cDNA and identification of a single point mutation responsible for camptothecin resistance. J. Biol. Chem. 268:1993;25463-25468.
9. Niimi S., Nakagawa K., Sugimoto Y., Nishio K., Fujiwara Y., Yokoyama S., Terashima Y., Saijo N. Mechanism of cross-resistance to a camptothecin analogue (CPT-11) in a human ovarian cancer cell line selected by cisplatin. Cancer Res. 52:1992;328-333.
10. Hendricks C.B., Rowinsky E.K., Grochow L.B., Donehower R.C., Kaufmann S.H. Effect of P-glycoprotein expression on the accumulation and cytotoxicity of topotecan (SK&F 104864), a new camptothecin analogue. Cancer Res. 52:1992;2268-2278.
11. Friedman H.S., Dolan M.E., Kaufman S.H., Colvin O.M., Griffith O.W., Moschel R.C., Schold S.C., Bigner D.D., Ali-Osman F. Elevated DNA polymerase α, DNA polymerase β, and DNA topoisomerase II in a melphalan-resistant rhabdomyosarcoma xenograft that is cross-resistant to nitrosourea and topotecan. Cancer Res. 54:1994;3487-3493.
12. Onishi Y., Oguro M., Kizaki H. A lymphoma cell line resistant to 4-piperidinopiperidine was less sensitive to CPT-11. Cancer Chemother. Pharmacol. 39:1997;473-478.
13. Azuma Y., Onishi Y., Sato Y., Kizaki H. Effects of protein tyrosine kinase inhibitors with different modes of action on topoisomerase activity and death of IL-2-dependent CTLL-2 cells. J. Biochem. 118:1995;312-318.
14. Scudiero D.A., Shoemaker R.H., Paull K.D., Monks A., Tierney S., Nofziger T.A., Currens M.J., Seniff D., Boyd M.R. Evaluation of a soluble tetrazolium/formazan assay for cell growth and drug sensitivity in culture using human and other tumor cell lines. Cancer Res. 48:1988;4827-4833.
15. Kuribayashi K., Hikata M., Hiraoka O., Miyamoto C., Furuichi Y. A rapid and efficient purification of poly(A)-mRNA by oligo(dT)-latex. Nucleic Acids Res. Symp. 19:1988;61-64.
16. 4-3-ketosteroid 5β-reductase of rat liver. FEBS Lett. 283:1991;215-218.
17. Clark A.R., Purdie C.A., Harrison D.J., Morris R.G., Bird C.C., Hooper L.M., Wyllie A.H. Thymocyte apoptosis induced by p53-dependent and independent pathway. Nature. 362:1993;849-852.
18. Hannun Y.A. Apoptosis and the dilemma of cancer chemotherapy. Blood. 89:1997;1845-1853.
19. Kondo S., Yin D., Morimura T., Takeuchi J. bcl-2 gene prevents induction of apoptosis in L1210 murine leukemia cells by SN-38, a metabolite of the camptothecin derivative CPT-11. Int. J. Oncol. 4(3):1994;649-654.
20. Tsujimoto Y., Cossman J., Jaffe E., Croce C.M. Cloning of the breakpoint of the neoplastic B cells with the t(14;18) chromosome translocation. Science. 226:1984;1097-1099.